Week of October 8, 2012: Mayne Pharma to Acquire Metrics; Sanofi, Bristol-Myers Squibb Restructure Plavix Alliance; and More - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Week of October 8, 2012: Mayne Pharma to Acquire Metrics; Sanofi, Bristol-Myers Squibb Restructure Plavix Alliance; and More

ePT--the Electronic Newsletter of Pharmaceutical Technology

AstraZeneca and Ardelyx have announced a worldwide exclusive licensing agreement for Ardelyx’s NHE3 inhibitor program, including the Phase II-ready lead compound RDX5791, for treating end-stage renal disease and chronic kidney disease. Under the agreement, AstraZeneca will pay $35 million up front, with development milestones of $237.5 million and milestones related to launch and commercialization, as well as tiered, double-digit royalties. AstraZeneca will assume the subsequent development costs and Ardelyx will conduct clinical trials in Phase II. As part of the transaction, Ardelyx has secured an option to copromote the product in the US, subject to agreed limitations. Read More

Mayne Pharma has agreed to acquire the CDMO Metrics for an upfront payment of $105 million, plus further payments of up to $15 million based on fiscal year (FY) 2013 performance. The deal is subject to regulatory approval and customary closing conditions. Read More

Sanofi and Bristol-Myers Squibb (BMS) have restructured their long-term alliance following the loss of exclusivity of Plavix (clopidogrel bisulfate) and Avapro (irbesartan)/Avalide (hydrochlorothiazide; irbesartan) in several major markets. Under the revised agreement, which will go into effect Jan. 1, 2013, BMS will return to Sanofi its rights to Plavix and Avapro/Avalide in all markets worldwide with the exception of Plavix in the US and Puerto Rico, giving Sanofi sole control and freedom to operate commercially. In exchange, BMS will receive royalty payments on Sanofi’s sales of branded and unbranded Plavix worldwide, excluding the US and Puerto Rico, and on sales of branded and unbranded Avapro/Avalide worldwide, in each case through 2018, and will receive a terminal payment of $200 million from Sanofi in December 2018. Plavix rights in the US and Puerto Rico will continue unchanged under the existing agreement through December 2019. Read More

A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here